L'assurance des professionnels de la santé
Location: France, Great East, La Wantzenau
Employees: 1001-5000
Phone: +33 1 71 14 32 33
Mentions in press and media 19
| Date | Title | Description |
| 14.03.2026 | Elaia Fuels Europe's Deep Tech Future with €134M Fund | Elaia has closed its €134 million DTS3 fund. This deep tech seed fund targets European B2B startups. It doubles prior deep tech allocations. Elaia partners with top research institutions. The fund invests €1M-€13M in early-stage ventures. F... |
| 12.03.2026 | Elaia closes third DeepTech Seed fund at €134 million as “European DeepTech is reaching escape velocity” | Paris-based VC firm Elaia has announced the closing of its third DeepTech Seed fund (DTS3) at €134 million, which is double the size of its previous DeepTech Seed funds. DTS3’s final closing includes support from longtime partners and new i... |
| 16.02.2026 | Elaia Secures €120 Million for New European B2B Tech Fund, Targets €300 Million | Elaia announces a €120 million first close for its Digital Venture Fund V (DV5). The fund targets €300 million. It will fuel European B2B technology startups. Investments span pre-Seed to Series B. Ticket sizes range from €1 million to €15 ... |
| 11.02.2026 | French VC Elaia reaches €120 million first close for new multi-stage B2B technology fund | Paris-based VC firm Elaia has announced the first close of its fifth Digital Venture Fund (DV5) at €120 million, with ambitions to scale to €300 million, to back European B2B technology startups from pre-Seed to Series B, deploying ticket s... |
| 11.02.2026 | Elaia’s Digital Venture Fund V reaches €120M at first close | Elaia has announced a first close of its fifth Digital Venture Fund (DV5) at €120 million. The fund will focus on investing in European B2B technology companies with strong intellectual property foundations, spanning both foundational infra... |
| 04.02.2026 | Andera Partners announces the final closing of Acto V at 1.1 billion euros, exceeding its hard cap. | PAN-EUROPEAN ACCELERATION: A FUND ALREADY IN ACTION This closing comes at a time when Andera Acto is stepping up its pan-European deployment. In 2025, the team set up a network of Senior Advisors in Belgium, Germany, and Italy, soon to be j... |
| 11.01.2026 | Enodia Therapeutics Secures €20.7M Seed Funding to Pioneer Protein Degradation with AI | Enodia Therapeutics, a pioneering biotech firm, secured a significant €20.7 million ($25 million) seed funding round. This vital capital propels its innovative small-molecule platform, a breakthrough approach targeting protein degradation a... |
| 11.01.2026 | Enodia Therapeutics Raises €20.7M to Target "Undruggable" Proteins with SEC61 Platform | Enodia Therapeutics, a Paris-based biotech, has secured €20.7 million ($25 million) in seed funding. Argobio Studio launched the company. Enodia develops small molecules. Its platform targets protein degradation at the point of synthesis. I... |
| 10.01.2026 | Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform | Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of ... |
| 09.01.2026 | Argobio Launches Enodia With €20.7 Million Seed Round To Develop Small Molecules For Protein Degradation | Argobio Studio announced it has launched Enodia Therapeutics and completed a €20.7 million ($25 million) seed financing to advance a small-molecule platform for targeted protein degradation at the point of protein synthesis, enabled by prot... |
Show more